Optimized anti-TL1A antibodies
AssigneesPrometheus Biosciences, Inc., Cedars-Sinai Medical Center
InventorsJeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
Life of this patent
Estimating the term…
Abstract
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Claims20
A nucleic acid encoding an antibody, or antigen binding portion thereof, that binds to tumor necrosis factor-like ligand 1A (TL1A), wherein the nucleic acid comprises:
- a nucleic acid sequence encoding a heavy chain variable region comprising:
- (a) a nucleic acid encoding a HCDR1 comprising the amino acid sequence set forth by SEQ ID NO:
- 553;
- (b) a nucleic acid encoding a HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOs:
- 554 to 564, or 574 to 577;
- and (c) a nucleic acid encoding a HCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOs:
- 565 to 568, or 579 to 581;
- and
- a nucleic acid sequence encoding a light chain variable region comprising:
- (a) a nucleic acid encoding a LCDR1 comprising an amino acid sequence set forth by any one of SEQ ID NOs:
- 569 or 570;
- (b) a nucleic acid encoding a LCDR2 comprising the amino acid sequence set forth by SEQ ID NO:
- 488;
- and (c) a nucleic acid encoding a LCDR3 comprising the amino acid sequence set forth by SEQ ID NO:
- 572.
A nucleic acid encoding an antibody, or antigen binding portion thereof, that binds to tumor necrosis factor-like ligand 1A (TL1A), wherein the nucleic acid comprises:
- a nucleic acid sequence encoding a heavy chain variable region comprising:
- (a) a nucleic acid encoding a HCDR1 comprising the amino acid sequence set forth by SEQ ID NO:
- 553;
- (b) a nucleic acid encoding a HCDR2 comprising the amino acid sequence set forth by SEQ ID NO:
- 554;
- and (c) a nucleic acid encoding a HCDR3 comprising the amino acid sequence set forth by SEQ ID NO:
- 565;
- and
- a nucleic acid sequence encoding a light chain variable region comprising:
- (a) a nucleic acid encoding a LCDR1 comprising the amino acid sequence set forth by SEQ ID NO:
- 569;
- (b) a nucleic acid encoding a LCCR2 comprising the amino acid sequence set forth by SEQ ID NO:
- 488;
- and (c) a nucleic acid encoding a LCDR3 comprising the amino acid sequence set forth by SEQ ID NO:
- 572.
A method of producing an antibody, or an antigen binding portion thereof, that binds to tumor necrosis factor-like ligand 1A (TL1A), wherein the method comprises
- (a) providing a host cell comprising an expression vector harboring a nucleic acid encoding the antibody, or the antibody binding portion thereof, wherein the nucleic acid comprises:
- a nucleic acid sequence encoding a heavy chain variable region comprising:
- (i) a nucleic acid encoding a HCDR1 comprising the amino acid sequence set forth by SEQ ID NO:
- 553;
- (ii) a nucleic acid encoding a HCDR2 comprising the amino acid sequence set forth by SEQ ID NO:
- 554;
- and (iii) a nucleic acid encoding a HCDR3 comprising the amino acid sequence set forth by SEQ ID NO:
- 565;
- and
- a nucleic acid sequence encoding a light chain variable region comprising:
- (i) a nucleic acid encoding a LCDR1 comprising the amino acid sequence set forth by SEQ ID NO:
- 569;
- (ii) a nucleic acid encoding a LCCR2 comprising the amino acid sequence set forth by SEQ ID NO:
- 488;
- and (iii) a nucleic acid encoding a LCDR3 comprising the amino acid sequence set forth by SEQ ID NO:
- 572;
- and
- (b) culturing the host cell under conditions to induce expression of the antibody or antibody portion from the host cell.
Dependencies are inferred from the claim text.